Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC
Shots:
- Innovent & Roche have entered into a collaboration & exclusive license agreement for developing IBI3009 to treat advanced SCLC
- As per the terms, Roche secures exclusive worldwide rights to develop, manufacture & commercialize IBI3009 plus will lead full development after early-stage studies, conducted jointly. Innovent will get $80M upfront, up to $1B development & commercial milestones as well as net-sales-based tiered royalties
- IBI3009, a novel DLL3-targeting ADC, has IND approvals in Australia, China & the US (P-I dosing started in Dec 2024). Designed using Innovent's TOPO1i platform, it shows strong anti-tumor activity, particularly in chemo-resistant tumors & has a favorable safety profile
Ref: Prnewswire | Image: Roche & Innovent Biologics
Related News:- Innovent Biologics Reports the P-II Trial Data of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
